Eli Lilly is trading 3.98% up at $1,256.84 as defensive healthcare-sector demand supports the move.

  • Investors rotated into defensive healthcare stocks after hotter-than-expected September inflation revived rate concerns and weighed on technology shares.
  • A new clinical-trial supply agreement and fresh Omvoh data were reported, but sources did not establish either as the reason for the gain.